Related Experiment Videos
Prophylactic indomethacin therapy for patent ductus arteriosus in very-low-birth-weight infants
Insights
Prophylactic indomethacin therapy in premature infants under 1000g significantly reduced major patent ductus arteriosus shunts and associated morbidities. This intervention proved beneficial for smaller infants, improving outcomes and reducing the need for surgical intervention.
Area of Science:
- Neonatology
- Pediatric Cardiology
- Pharmacology
Background:
- Patent ductus arteriosus (PDA) is common in premature infants.
- Subclinical PDA can lead to significant complications.
- Early intervention strategies are crucial for improving outcomes.
Purpose of the Study:
- To evaluate the efficacy of prophylactic indomethacin in preventing hemodynamically important patent ductus arteriosus (PDA) shunts in premature infants.
- To assess the impact of indomethacin on morbidity, including surgical ligation and oxygen therapy duration.
Main Methods:
- A double-blind, placebo-controlled study involving 47 premature infants (<1700 g) with subclinical PDA.
- Infants received either indomethacin or placebo around 2.9 days of age.
- Outcomes were analyzed based on infant weight strata (above and below 1000 g).
Main Results:
- In infants weighing 1000 g or less, indomethacin significantly reduced the incidence of major PDA shunts compared to placebo (10/12 vs. 2/10).
- Indomethacin therapy in smaller infants was associated with fewer surgical ligations, shorter oxygen therapy duration, and faster regain of birth weight.
- In infants >1000 g, no significant differences in shunt incidence, surgical ligations, or oxygen therapy duration were observed between groups.
Conclusions:
- Prophylactic indomethacin is effective in preventing large ductus arteriosus shunts and reducing morbidity in premature infants weighing under 1000 g.
- The benefits of indomethacin appear weight-dependent, with significant advantages observed in the smallest infants.
- This suggests a targeted approach to indomethacin use in high-risk premature neonates.
Abstract:
We performed a double-blind, controlled study of prophylactic indomethacin therapy in 47 premature infants (less than 1700 g) who had subclinical patent ductus arteriosus. They received either indomethacin or placebo at a mean age of 2.9 days. Among the 25 infants weighing more than 1000 g, a hemodynamically important ductus shunt developed in only four of the 14 given placebo. The incidence of important shunts, the number of surgical ligations, and the duration of oxygen therapy were not appreciably different between the study groups. In contrast, among the 22 infants who weighed 1000 g or less, a major ductus shunt developed in 10 of the 12 given placebo. In the smaller infants indomethacin therapy was associated with a significantly lower incidence of major shunts, fewer surgical ligations, a decreased duration of oxygen therapy, and fewer days necessary to regain birth weight. We conclude that prophylactic indomethacin therapy in infants weighing under 1000 g prevents the later development of large ductus shunts and decreases morbidity.